Immix Biopharma, Inc. - 8-K Filing
Immix Biopharma announced that all four MRD-negative relapsed/refractory AL Amyloidosis patients presented at ASH 2025 have converted to complete response (CR), increasing the CR rate in NEXICART-2 trial to 95% (19/20). All CRs were achieved within one year of follow-up, with no relapses observed. The next update is expected late September 2026. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $IMMX